- Home
- BSET vs ALXO Comparison
BSET vs ALXO Comparison
Compare BSET & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSET | ALXO |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.6M | 205.9M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSET | ALXO |
|---|---|---|
| Price | $19.38 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 66.6K | ★ 818.2K |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 163.06 | 26.36 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $52.35 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $0.51 |
| 52 Week High | $22.26 | $2.66 |
Technical Indicators
Market Signals| Indicator | BSET | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 48.89 |
| Support Level | $14.11 | $1.96 |
| Resistance Level | $22.26 | $2.23 |
| Average True Range (ATR) | 0.76 | 0.13 |
| MACD | -0.36 | -0.02 |
| Stochastic Oscillator | 19.31 | 24.53 |
Price Performance
Historical ComparisonAbout BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.